Eva Gonzalez-Barca

12PUBLICATIONS
61CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursPredictive and prognostic markersHaematology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Sep 24, 2026
Phase 1, open-label, multicenter study of sovleplenib (HMPL-523) in patients with relapsed or refractory lymphoma.

|Nov 26, 2025
Asparaginase Hypersensitivity Reactions in NK/T-Cell Lymphomas.

Javier Varela Gonzalez-Aller, Pablo Nadal, Salome Cañizares

|Jul 16, 2025
Tafasitamab plus lenalidomide as salvage therapy in diffuse large B-cell lymphoma: real-world experience from GELTAMO.

Antonio Gutierrez, Izaskun Zeberio, Francisco Javier Peñalver

|Apr 09, 2025
The role of miR-150-5p/E2F3/survivin axis in the pathogenesis of plasmablastic lymphoma and its therapeutic potential.

Miriam Verdú-Bou, Maria Joao Baptista, Marcelo Lima Ribeiro

|Mar 07, 2023
Extranodal natural killer/T-cell lymphoma nasal type in a western population: Molecular profiling identifies new therapeutic targets.

Eva Gonzalez Barca, Laura Tomás-Roca, Anna Esteve

|Oct 29, 2021
A real-life overview of a hematopoietic cell transplant program throughout a four-year period, including prospective registry, exclusion causes and final donor selection.

R Parody, I Sánchez-Ortega, A Mussetti

Pageof 2

Frequent Collaborators

3 joint publications

Eva Domingo

2 joint publications

Maria Joao Baptista

2 joint publications

José-Tomas Navarro

2 joint publications

Annette M Staiger